Recent posts
-
San Diego’s life sciences news picked up a bit last week amid fresh signs of the area’s growing prominence in the laboratory tools and diagnostics sectors.
—Carlsbad, CA-based Helixis, a startup maker... Read more »
-
From Australia comes word that San Diego-based Amylin Pharmaceuticals’ biggest drug, exenatide (Byetta), has been caught up in a controversy over a diabetes report co-sponsored by Amylin’s marketing partner, Eli Lilly & Co.
The... Read more »
-
Word that several San Diego companies successfully raised funds punctuated an otherwise light week for life sciences news here. A rundown of the highlights:
—Synthetic biology company Verdezyne received a $1.7 million Small... Read more »
-
San Diego’s Ardea Biosciences (NASDAQ: RDEA) appears to have stubbed a toe in its development of RDEA 594 as a first-line treatment for gout. Data presented at a medical meeting in Philadelphia today... Read more »
-
In wake of last week’s Algae Biomass Summit, we thought now might be a good time to take stock of San Diego’s biofuels/biomass energy sector. After identifying a mini-cluster of eight algae... Read more »
-
A quiet epilogue to last spring’s heated Amylin proxy battle was the lead story in an otherwise slow week for San Diego life sciences news.
—Eastbourne Capital, which won a partial... Read more »
-
San Diego’s Illumina (NASDAQ: [[ticker: ILMN]]) has licensed worldwide rights to commercially develop Orchid Cellmark’s proprietary single base nucleotide extension technology for forensics and diagnostics. Princeton, N.J.-based Orchid (NASDAQ: ORCH)... Read more »
-
The life sciences news was relatively light over the last week, except perhaps for Sequenom, the medical diagnostics company that has yet to publicly disclose much about its misconduct in handling... Read more »
-
The 2009 Algae Biomass Summit gets underway in San Diego today, offering the latest sign of the algae biofuels sector that has bloomed in San Diego in recent years. Cleantech San... Read more »
-
San Diego’s little Cibus Global is preparing to one day take on Monsanto, the Fortune 500 agri-industry colossus and leading producer of genetically engineered seed. The bioscience company last month formed... Read more »
-
One-time biotech darling Neurocrine Biosciences (NASDAQ: NBIX) says it is vacating one of two buildings at its headquarters campus to save $27 million a year. The company paid an immediate $4... Read more »
-
In what is shaping up as the battle of San Diego’s biotechnology tools titans, Life Technologies (NASDAQ: LIFE) has filed a patent-infringement suit against rival Illumina, claiming that some of Illumina’s... Read more »
-
San Diego’s Quidel, which signaled it would report better-than-expected quarterly results on Sept. 10, isn’t the only San Diego biomedical company to get a boost from worries about swine flu. At least... Read more »
-
The chief medical officer of Tioga Pharmaceuticals, a start-up working on a drug for irritable bowel syndrome, is in North Carolina. The company’s regulatory team is in San Francisco. Its chief operating... Read more »
-
[Corrected 9/4/09, 12:25 am. See below.]
Avanir Pharmaceuticals (NASDAQ: AVNR) announcement last month that its drug DMQ reduced involuntary fits of laughter and crying in neurological patients came... Read more »
-
Biotechnology start-ups have long been seen as fearless innovators, embracing experimental technologies, like gene therapy, that big pharmaceutical companies won’t touch. But the news flow from San Diego this summer suggests... Read more »
-
Three months ago, San Diego’s Sequenom disclosed that the launch of a new prenatal test for Down syndrome would be delayed because scientific data had been mishandled. So what have we learned... Read more »
-
San Diego’s Acadia Pharmaceuticals (NASDAQ: ACAD) has filed a shelf registration to sell up to 7 million shares at a maximum share price of $4.17. The company, which is working on a drug... Read more »
-
TorreyPines Therapeutics (NASDAQ: TPTX) has found a new solution to its cash woes: a merger with Novato, CA-based Raptor Pharmaceuticals. To pull off the deal, however, TorreyPines must overcome an old problem:... Read more »
-
Inovio Biomedical (AMEX: INO), a San Diego company developing DNA-based vaccines against cervical cancer and other diseases, has raised $30 million from the direct sale of 11.1 million shares and 2.8... Read more »
